Endothelial to Mesenchymal Transition in the Cardiogenesis and Cardiovascular Diseases

Overview

Journal Curr Cardiol Rev

Publisher Bentham Science Publishers

Specialty Cardiology & Vascular Diseases

Date 2019 Aug 9

PMID 31393254

Citations 16

Authors

Taha Anbara

Masuomeh Sharifi

Nahid Aboutaleb

Affiliations

Soon will be listed here.

Abstract

Today, cardiovascular diseases remain a leading cause of morbidity and mortality worldwide. Endothelial to mesenchymal transition (EndMT) does not only play a major role in the course of development but also contributes to several cardiovascular diseases in adulthood. EndMT is characterized by down-regulation of the endothelial proteins and highly up-regulated fibrotic specific genes and extracellular matrix-forming proteins. EndMT is also a transforming growth factor- β-driven (TGF-β) process in which endothelial cells lose their endothelial characteristics and acquire a mesenchymal phenotype with expression of α-smooth muscle actin (α-SMA), fibroblastspecific protein 1, etc. EndMT is a vital process during cardiac development, thus disrupted EndMT gives rise to the congenital heart diseases, namely septal defects and valve abnormalities. In this review, we have discussed the main signaling pathways and mechanisms participating in the process of EndMT such as TGF-β and Bone morphogenetic protein (BMP), Wnt#, and Notch signaling pathway and also studied the role of EndMT in physiological cardiovascular development and pathological conditions including myocardial infarction, pulmonary arterial hypertension, congenital heart defects, cardiac fibrosis, and atherosclerosis. As a perspective view, having a clear understanding of involving cellular and molecular mechanisms in EndMT and conducting Randomized controlled trials (RCTs) with a large number of samples for involving pharmacological agents may guide us into novel therapeutic approaches of congenital disorders and heart diseases.

Citing Articles

Acute exposure to electronic cigarette components alters mRNA expression of pre-osteoblasts.

Dabdoub S, Greenlee A, Abboud G, Brengartner L, Zuiker E, Gorr M FASEB J. 2024; 38(17):e70017.

PMID: 39213037 PMC: 11371384. DOI: 10.1096/fj.202302014RRR.

Lack of basic rationale in epithelial-mesenchymal transition and its related concepts.

Cao Y Cell Biosci. 2024; 14(1):104.

PMID: 39164745 PMC: 11334496. DOI: 10.1186/s13578-024-01282-w.

Endocardial HDAC3 is required for myocardial trabeculation.

Jang J, Bentsen M, Kim Y, Kim E, Garg V, Cai C Nat Commun. 2024; 15(1):4166.

PMID: 38755146 PMC: 11099086. DOI: 10.1038/s41467-024-48362-6.

The role of cardiac microenvironment in cardiovascular diseases: implications for therapy.

Yao J, Chen Y, Huang Y, Sun X, Shi X Hum Cell. 2024; 37(3):607-624.

PMID: 38498133 DOI: 10.1007/s13577-024-01052-3.

Tongxinluo Activates PI3K/AKT Signaling Pathway to Inhibit Endothelial Mesenchymal Transition and Attenuate Myocardial Fibrosis after Ischemia-Reperfusion in Mice.

Wei Y, Hou Y, Yin Y, Li Z, Liu Y, Han N Chin J Integr Med. 2024; 30(7):608-615.

PMID: 38386252 DOI: 10.1007/s11655-024-3652-5.

References

Bischoff J, Casanovas G, Wylie-Sears J, Kim D, Bartko P, Guerrero J . CD45 Expression in Mitral Valve Endothelial Cells After Myocardial Infarction. Circ Res. 2016; 119(11):1215-1225. PMC: 5215059. DOI: 10.1161/CIRCRESAHA.116.309598. View

Chen X, Lv R, Zhang W, Yan Y, Li P, Dong W . Inhibition of myocyte-specific enhancer factor 2A improved diabetic cardiac fibrosis partially by regulating endothelial-to-mesenchymal transition. Oncotarget. 2016; 7(21):31053-66. PMC: 5058738. DOI: 10.18632/oncotarget.8842. View

Renz M, Otten C, Faurobert E, Rudolph F, Zhu Y, Boulday G . Regulation of β1 integrin-Klf2-mediated angiogenesis by CCM proteins. Dev Cell. 2015; 32(2):181-90. DOI: 10.1016/j.devcel.2014.12.016. View

Kaneko K, Li X, Zhang X, Lamberti J, Jamieson S, Thistlethwaite P . Endothelial expression of bone morphogenetic protein receptor type 1a is required for atrioventricular valve formation. Ann Thorac Surg. 2008; 85(6):2090-8. DOI: 10.1016/j.athoracsur.2008.02.027. View

Zeisberg E, Tarnavski O, Zeisberg M, Dorfman A, McMullen J, Gustafsson E . Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007; 13(8):952-61. DOI: 10.1038/nm1613. View

Cheng S, Shao J, Behrmann A, Krchma K, Towler D . Dkk1 and MSX2-Wnt7b signaling reciprocally regulate the endothelial-mesenchymal transition in aortic endothelial cells. Arterioscler Thromb Vasc Biol. 2013; 33(7):1679-89. PMC: 3837473. DOI: 10.1161/ATVBAHA.113.300647. View

Zhou Z, Tang A, Wong W, Bamezai S, Goddard L, Shenkar R . Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling. Nature. 2016; 532(7597):122-6. PMC: 4864035. DOI: 10.1038/nature17178. View

Kostina A, Uspensky V, Irtyuga O, Ignatieva E, Freylikhman O, Gavriliuk N . Notch-dependent EMT is attenuated in patients with aortic aneurysm and bicuspid aortic valve. Biochim Biophys Acta. 2016; 1862(4):733-740. DOI: 10.1016/j.bbadis.2016.02.006. View

Gong H, Lyu X, Wang Q, Hu M, Zhang X . Endothelial to mesenchymal transition in the cardiovascular system. Life Sci. 2017; 184:95-102. DOI: 10.1016/j.lfs.2017.07.014. View

10.

Garside V, Chang A, Karsan A, Hoodless P . Co-ordinating Notch, BMP, and TGF-β signaling during heart valve development. Cell Mol Life Sci. 2012; 70(16):2899-917. PMC: 4996658. DOI: 10.1007/s00018-012-1197-9. View

11.

de la Pompa J . Notch signaling in cardiac development and disease. Pediatr Cardiol. 2009; 30(5):643-50. DOI: 10.1007/s00246-008-9368-z. View

12.

Combs M, Yutzey K . Heart valve development: regulatory networks in development and disease. Circ Res. 2009; 105(5):408-21. PMC: 2777683. DOI: 10.1161/CIRCRESAHA.109.201566. View

13.

Kim J, Kim J, Lee S, Kepreotis S, Yoo J, Chun J . Cytokine-Like 1 Regulates Cardiac Fibrosis via Modulation of TGF-β Signaling. PLoS One. 2016; 11(11):e0166480. PMC: 5105950. DOI: 10.1371/journal.pone.0166480. View

14.

Bartko P, Dal-Bianco J, Guerrero J, Beaudoin J, Szymanski C, Kim D . Effect of Losartan on Mitral Valve Changes After Myocardial Infarction. J Am Coll Cardiol. 2017; 70(10):1232-1244. PMC: 5679094. DOI: 10.1016/j.jacc.2017.07.734. View

15.

Germani A, Foglio E, Capogrossi M, Russo M, Limana F . Generation of cardiac progenitor cells through epicardial to mesenchymal transition. J Mol Med (Berl). 2015; 93(7):735-48. DOI: 10.1007/s00109-015-1290-2. View

16.

Kang Z, Ji Y, Zhang G, Qu Y, Zhang L, Jiang W . Ponatinib attenuates experimental pulmonary arterial hypertension by modulating Wnt signaling and vasohibin-2/vasohibin-1. Life Sci. 2016; 148:1-8. DOI: 10.1016/j.lfs.2016.02.017. View

17.

Hopper R, Moonen J, Diebold I, Cao A, Rhodes C, Tojais N . In Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and Its Target Slug. Circulation. 2016; 133(18):1783-94. PMC: 4856565. DOI: 10.1161/CIRCULATIONAHA.115.020617. View

18.

Kato H, Fu Y, Zhu J, Wang L, Aafaqi S, Rahkonen O . Pulmonary vein stenosis and the pathophysiology of "upstream" pulmonary veins. J Thorac Cardiovasc Surg. 2013; 148(1):245-53. DOI: 10.1016/j.jtcvs.2013.08.046. View

19.

Welch-Reardon K, Wu N, Hughes C . A role for partial endothelial-mesenchymal transitions in angiogenesis?. Arterioscler Thromb Vasc Biol. 2014; 35(2):303-8. PMC: 4911209. DOI: 10.1161/ATVBAHA.114.303220. View

20.

Sucov H, Gu Y, Thomas S, Li P, Pashmforoush M . Epicardial control of myocardial proliferation and morphogenesis. Pediatr Cardiol. 2009; 30(5):617-25. DOI: 10.1007/s00246-009-9391-8. View